LYTACs, or Lysosome Targeting Chimeras, are cutting-edge molecules designed to target and degrade specific proteins within cells by directing them to the lysosome, a cellular organelle responsible for degradation. By harnessing the cell’s natural lysosomal degradation pathway, LYTACs can target and eliminate disease-associated proteins present outside of cells, including those involved in inflammation, cancer, and neurodegenerative disorders. This innovative approach offers a promising avenue for therapeutic intervention, with the potential to address a wide range of diseases that were previously challenging to target using traditional drug modalities. As research in LYTAC technology continues to advance, it holds significant promise for transforming the landscape of medicine and improving patient outcomes.